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Abstract This prospective observational study evaluates
the validity of an algorithm for assigning patients to a
multidisciplinary modularized managed care headache
treatment program. N = 545 chronic headache sufferers
[migraine (53.8 %), migraine ? tension type (30.1 %),
tension type (8.3 %) or medication overuse headache
(6.2 %), other primary headaches (1.5 %)] were assigned
to one of four treatment modules differing with regard to
the number and types of interventions entailed (e.g.,
medication, psychological intervention, physical therapy,
etc.). A rather simple assignment algorithm based on
headache frequency, medication use and psychiatric
comorbidity was used. Patients in the different modules
were compared with regard to the experienced burden of
disease. 1-year follow-up outcome data are reported
(N = 160). Headache frequency and analgesic consump-
tion differed significantly among patients in the modules.
Headache-related disability was highest in patients with
high headache frequency with/without medication overuse
or psychiatric comorbidity (modules 2/3) compared to
patients with low headache frequency and medication
(module 0). Physical functioning was lowest in patients with
chronic headache regardless of additional problems (modules
1/2/3). Psychological functioning was lowest in patients with
severe chronicity with/without additional problems (module
2/3) compared to headache suffers with no/moderate chro-
nicity (module 0/1). Anxiety or depression was highest in
patients with severe chronicity. In 1-year follow-up, headache
frequency (minus 45.3 %), consumption of attack-aborting
drugs (minus 71.4 %) and headache-related disability
decreased (minus 35.9 %). Our results demonstrate the clin-
ical effectiveness and the criterion validity of the treatment
assignment algorithm based on headache frequency, medi-
cation use and psychiatric comorbidity.
Keywords Integrated care  Multidisciplinary
modularized treatment program  Outcome study 
Headache-related disability 
Headache-related quality of life  Chronic headache
Introduction
Headache (HA) is one of the most common types of chronic
pain. In adults, about 4 % experience HA episodes on a near
daily or daily basis [1]. Chronic headache imposes an immense
burden on the individual and society because of significant
morbidity and indirect and direct costs. The annual value of
lost productivity in the United States is estimated to reach $13
billion for migraine and $19 billion for all headache disorders
[2, 3]. Headache-related disability (HRD) is reported by more
than 85 % of migraineurs. Headaches reduce the quality of
life, decrease social and job functioning, and increase utili-
zation of health care systems [4, 5]. Accordingly, the World
Health Organization (WHO) has ranked migraine among the
top 20 most disabling medical diseases worldwide [6].
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Despite advances in the acute and preventive treatment
of primary headaches, many headache patients remain
misdiagnosed and undertreated [7–10]. Headache sufferers
are often dissatisfied with the health care they receive. On
average, patients with chronic headache utilize more health
care resources than patients with other chronic diseases, for
example consuming twice as much medication [11, 12].
Cross-sectional and longitudinal epidemiological studies
as well as clinical studies, family and twin studies have
repeatedly reported a high comorbidity between headache
and mood and anxiety disorders. Psychiatric disorders may
interfere with headache treatment. HA patients with a
comorbid mood or anxiety disorders report lower health-
related quality of life (HRQoL) [13, 14], have a poorer
prognosis and respond less well to treatment. The preva-
lence and impact of psychiatric disorders in headache
patients underline the necessity for screening patients as
part of routine clinical care and not only of refractory
patients in tertiary headache centers [15].
In clinical practice, there is a lack of multidisciplinary
headache treatment programs that entail a comprehensive
assessment including a headache diagnosis according to
ICDH-II criteria [16], screening for psychiatric comorbid-
ity, craniomandibular dysfunctioning and musculoskeletal
disorders, and provide treatment according to clinical
guidelines [17, 18]. Unfortunately, little is known about
such integrated headache programs and the patients
participating in such programs [19, 20].
In 2005, Diener and co-workers launched the West
German Headache Center, a managed and modularized
healthcare system for chronic headache patients [21, 22]
that was rated by the Harvard business school as one of the
best medical programs worldwide [23]. Later, centers in
Berlin, Munich and Jena followed. Primarily, this paper
focuses on the validity of patient assignment to the treat-
ment modules of our integrated headache care program.
Specifically, patients in the different modules were com-
pared with regard to pain-related disability, health-related
quality of life and psychological distress. For a subset of
patients, we also report 1-year follow-up data of patients
with frequent or difficult to treat headaches. Detailed data
on the program’s cost-effectiveness have been reported
elsewhere [24].
Methods
The Headache Center Berlin (HCB)
The Headache Center Berlin started in 07/2006 as a tertiary
outpatient headache clinic. Treatment is multidisciplinary
with daily treatment sessions. Additional inpatient treat-
ment facilities (5 beds) are available for patients with
medication overuse and severe psychiatric comorbidity.
The HCB cooperates with a network of primary care
physicians and headache specialists (secondary care). All
network partners are connected with the HCB by specifi-
cally designed online documentation software [25]. At the
HCB, European Headache Federation guidelines for the
organization of headache clinics are implemented [26].
Study design
This prospective study was done to evaluate the new
treatment approach used in the HCB. Adult patients
([18 years) with frequent and\or difficult to treat head-
ache diagnoses of migraine (M), tension-type headache
(TTH), and medication overuse headache (MOH) were
consecutively enrolled within a time period of 18 months
(11/2006–04/2008). Headache diagnoses were made
according to ICHD-II criteria [16] by a board-certified
neurologist (TMW). The baseline data of the total cohort
were used for determining the validity of treatment
assignment. A representative subgroup of these patients
completed treatment during this time period. For these,
we report the 1-year follow-up data. The remaining
patients followed the treatment program. A reduction of
headache frequency (days with headache/month) of[50 %
was defined as treatment success and served as primary
outcome parameter. Secondary outcomes were changes in
headache-related disability, anxiety and depression and
analgesic use. All patients signed a written informed con-
sent form. The project was approved by the local Ethics
Committee.
Assessment
Patients were referred by physicians or specialists when
headache treatment failed. In addition, health insurance
companies identified eligible patients on the basis of
inpatient data, sick leave or records of prescribed medi-
cation. Finally, self-referrals were encouraged by media
coverage. Patients kept a headache diary for at least
4 weeks prior to the first study visit. All patients underwent
an initial comprehensive assessment by a neurologist, a
psychologist and a physical therapist, and completed
several questionnaires assessing mood, headache-related
disability and health-related quality of life (see below for
details). A detailed headache history was taken, patients
underwent a physical exam, and a HA diagnosis was made
according to ICHD-II criteria [16]. If necessary, additional
diagnostic tests (imaging, blood test, etc.) were run. The
psychologist obtained information about the patient’s level
of stress, emotional well-being, job satisfaction, life events,
and data on possible psychological HA triggers were col-
lected. Mental disorders were assessed based on ICD-10
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[27], which is the standard classification system used in the
German health system. A physical therapist examined
posture and muscle function. Subsequent to the assessment,
both team and patient met in a pain conference and made a
joint decision about further treatment.
Treatment
As stated earlier, the managed care system entails a mod-
ularized treatment protocol. Patients were assigned to one
of four treatment modules taking into consideration head-
ache frequency, medication overuse and psychiatric
comorbidity. Typically, treatment duration is 1 year.
Module 0: no or little chronicity
Patients assigned to module 0 have a maximum of 5 HA
days/month. Patients are referred back to primary care
physicians with recommendation for improved headache
management (e.g. change of medication).
Module 1: moderate chronicity
Patients with a HA frequency between 6 and\10 HA days/
month and \10 days with intake of analgesics/triptans are
assigned to this module. Treatment includes education and
patient self-management for preventing headache episodes.
Medication is optimized if necessary.
Module 2: severe chronicity
Patients with more than 10 HA days/month and more than
10 days with intake of analgesics/triptans are assigned to
module 2. Patients receive module 1 treatment with a
maximum of 12 additional outpatient sessions on 5 con-
secutive days from 9.00 a.m. to 4.00 p.m. The program
entails group sessions and individual appointments with
the neurologist, psychologist and the physical therapist.
The neurologist provides headache education (90 min per
day). The psychologist provides cognitive-behavioral pain
management. The physical training comprises endurance
sport, physical therapy and Nordic walking (60 min per
day).
Module 3: severe chronicity with additional problems
Patients with more than 15 HA days/month and more than
15 days with intake of analgesics/triptans and severe psy-
chiatric comorbidity are assigned to this module. Aside
from participating in the outpatient program of module 2,
they are hospitalized for 5 up to a maximum of 7 days and
undergone drug withdrawal. Treatment entails initiating
adequate acute and prophylactic drug management.
Study patients
During a time period of 18 months (11/2006–04/2008), a
cohort of 545 headache sufferers was consecutively refer-
red to the HCB, which started in 07/2006 with a new
modularized headache managed care program. Baseline
data of these patients (N = 545) were available for vali-
dation of criterion-based patient assignment to the present
modularized headache treatment program. With the
exception of patients suffering from medication overuse
headache, patients with secondary headaches were exclu-
ded. Of the total cohort, N = 83 patients were assigned to
module 0, N = 158 patients to module 1, N = 249 to
module 2 and N = 55 patients to module 3.
During the 18-month study period N = 160 patients
completed the treatment, while the remaining patients
followed treatment program. For these, 12-month follow-
up outcome data are reported. Of these, N = 47 (29.4 %)
had been assigned to module 1, N = 97 (60.6 %) to
module 2 and N = 16 (10 %) to module 3.
Questionnaires
All questionnaires were administered on a pocket PC using
AC-STB software from Akkaya company, Ko¨ln, Germany
[24, 25].
Headache-related disability
The Migraine Disability Assessment (MIDAS) Question-
naire [28, 29] was developed to assess headache-related
disability. It contains five questions assessing the number
of missed days (full or with substantial loss of productivity)
at work, household chores, and leisure time. Reliability and
validity of the MIDAS have extensively been demonstrated
[28–30]. The total MIDAS score can be used to grade
migraine-related disability [grade 1 (minimal disability):
1–5 points, grade 2 (mild): 6–10 points, grade 3 (moder-
ate): 11–20 points, grade 4 (severe): [20 points] [28].
Headache frequency (past 3 months) and intensity are
assessed by two additional MIDAS items.
Chronic Pain Grade Questionnaire (CPGQ)
The CPGQ [31] consists of 6 items assessing pain intensity
or disability on 11-point numerical rating scales ranging
from ‘‘0’’ to ‘‘10’’. In addition, the number of days with
disability during the past 3 months is obtained. Using an
empirically derived and validated grading system, severity
is divided into five categories: grade 0 (pain free), grade 1
(low disability, low-pain intensity), grade 2 (low disability,
high-pain intensity); grade 3 (high disability, moderately
J Headache Pain (2012) 13:379–387 381
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limiting pain); and grade 4 (high disability, severely lim-
iting pain). Reliability and validity of the CPGQ have been
shown for the German version [32].
Health-related quality of life (HRQoL)
Health-related quality of life was assessed using the
German version of the 12 item-Short Form Health Survey
(SF12 [33], German version: [34]). The SF12 contains 2
subscales of functioning (‘‘physical’’/‘‘psychological’’).
The SF12 is reliable and valid, norms for the general
population are available [34].
Anxiety and depression
The Hospital Anxiety and Depression Scale (HADS,
(German: [35]) contains seven items each for assessing
depression and anxiety. The HADS is recommended for
patients with somatic problems [14]. In its original version,
a score between 0 and 7 is considered to be in the normal
range, a score between 8 and 10 as being slightly elevated,
and a score of 11 and higher as indicating the probable
presence of a mood or anxiety disorder.
Data analysis
Depending on the type of outcome variable, differences
between modules were computed either with one-way
analysis of variances (ANOVA) followed by Tukey’s HSD
post hoc tests for all pairwise contrasts or by chi-square
tests. Treatment data were computed either with Student
t test or Mann–Whitney U test when variables were not
normally distributed. All analyses were performed using
Predictive Analytics SoftWare (PASW) by SPSS. A p
value of 0.05 was considered as significant.











Age (year; M, SD) 43.08 (12.94) 42.70 (13.15) 43.94 (12.61) 42.50 (12.89) 43.90 (13.94)
N, females (%) 489 (89.7) 77 (92.8) 145 (91.8) 222 (89.2) 45 (81.8)
HA diagnosis (%)
MigraineA 293 (53.8) 55 (66.3) 90 (57.0) 118 (47.4) 30 (54.5)
Tension-type HA (%)A 43 (8.3) 3 (3.6) 6 (3.8) 32 (12.9) 4 (7.3)
Migraine ? TTH (%)A 164 (30.1) 21 (25.3) 55 (34.8) 73 (29.3) 15 (27.3)
Migraine ? other HA disorders (%)B 13 (2.4) 1 (1.2) 1 (0.6) 10 (4.0) 1 (1.8)
TTH ? other HA disorders (%)B 3 (0.6) 0 (0) 0 (0) 2 (0.8) 1 (1.8)
Migraine ? TTH ? other HA disorders
(%)B
1 (0.2) 1 (1.2) 0 (0) 0 (0) 0 (0)
Other HA disorders (%)B 16 (2.9) 1 (1.2) 5 (3.2) 9 (3.6) 1 (1.8)
MOH only (%)C 8 (1.5) 0 (0) 0 (0) 5 (2.0) 3 (5.5)
MOH (w/o other HA disorders; %)D 23 (4.2) 0 (0) 3 (1.9) 13 (5.2) 7 (12.7)
HA duration (year; M, SD) 20.69 (12.65) 19.85 (13.01) 22.09 (12.28) 19.59 (12.92) 22.86 (11.52)
MIDAS (M, SD)
Headache frequency (last 3 months) 28.43 (23.11) 8.45a (3.76) 22.39b (9.62) 35.59c (25.66) 43.55d (29.64)
Headache intensity (last 3 months) 6.37 (2.00) 6.40a (2.12) 6.42a (1.82) 6.32a (2.07) 6.42a (2.04)
Analgesic use (N days/month, M, SD) 8.84 (10.24) 4.48a (4.91) 6.47a (6.96) 9.13b (8.93) 20.85c (17.9)
Medication doses (N per months; M, SD) 18.77 (28.58) 8.99a (4.91) 12.96a (10.8) 17.53a (17.1) 55.8b (69.34)
Differences between modules were computed either with one-way analysis of variances (ANOVA [49]) or with v2 tests, depending on the type of
variable. Means with different lowercase superscripts differ significantly (Tukey’s HSD)
HA headache, MOH medication overuse headache, TTH tension-type HA
? Headache diagnosis was missing for two patients, one each in modules 0 and 1. Hence, percent values do not add up to 100
A With or without MOH
B Other HAs refer to all HA diagnoses except MOH
C Underlying primary headache not definable
D This refers to the total number of patients with an MOH diagnosis in the total sample or the modules




Table 1 shows sociodemographics, diagnoses and head-
ache characteristics at baseline of the total cohort. There
were no significant differences in headache diagnoses,
headache characteristics and sociodemographics of the
subgroup of treated patients in comparison with the total
cohort.
Comparison of modules
There was no significant difference between patients in the
four modules with regard to age (p [ 0.5) and sex pro-
portion (p [ 0.15). The vast majority of patients suffered
from migraine alone or in combination with tension-type or
other headaches. For the past 3 months, patients reported
on average a headache frequency of 28.43 ± 23.11 days
which differed significantly across groups (F(3,541) =
51.16, p \ 0.001). As illustrated in Table 1 and confirmed
by significant pairwise post hoc contrasts, headache fre-
quency increased significantly from modules 0 to 1, 1 to 2,
and 2 to 3. Headache intensity was on average 6.37 ± 2.00
with no significant difference between modules (p [ 0.9).
Patients relied on analgesics on an average of 8.84 ±
10.24 days per month. Analgesic uses varied significantly
across modules (F(3,539) = 40.35, p \ 0.001) with
patients in modules 0 and 1 using significantly less anal-
gesics than patients in modules 2 and 3, and patients in
module 3 having a significantly more frequent use than
patients in module 2 (see Table 2). Patients reported an
average consumption of medication doses of 6.34 ± 10.15
per month which varied significantly across the modules
(F(3,539) = 44.14, p \ 0.001) with patients in module 3
using the greatest amount of medication compared to all
other patients. Patients in modules 0, 1 and 2 did not sig-
nificantly differ with regard to the number of medication
doses.
Headache-related disability
The MIDAS total score differed significantly between
modules (F(3,541) = 23.14, p \ 0.001). Post hoc Tukey
contrasts revealed that patients in module 0 had a signifi-
cantly lower MIDAS total score compared to all other
patients. Patients in module 1 had significantly lower
MIDAS total scores than patients in modules 2 and 3, with
the latter two not differing significantly (see Table 2).
Consistently, the percentage of patients having a MIDAS
grade III or IV increased significantly from module 0 to
module 3 (v2(9) = 49.4, p \ 0.001; see Table 2).
Chronic Pain Grading Questionnaire (von Korff index)
Similar to the MIDAS grades, the von Korff grades of
severity differed significantly between modules (v2(9) =
47.03, p \ 0.001; see Table 2). The proportion of patients
with a severity grade of III or IV increased from modules 0
(27 %) to 3 (72 %) with modules 1 (50 %) and 2 (57 %)
lying in between.
Anxiety and depression
One-way ANOVAs revealed significant differences with
regard to HADS anxiety (F(3,541) = 23.84, p \ 0.001)
and depression scores (F(3,541) = 22.94, p \ 0.001). Post
hoc contrasts (Tukey HSD) showed that anxiety and
depression levels of patients in modules 0 and 1 were not
significantly different. However, both groups reported
Table 2 Pain-related disability (MIDAS, von Korff index)
Total Module 0 Module 1 Module 2 Module 3
MIDAS
Total score (M, SD) 43.43 (42.44) 18.49a (17.20) 33.77b (29.12) 53.9c (48.52) 61.42c (48.55)
Grade 1 (N, %) 63 (11.6) 19 (22.9) 16 (10.1) 26 (10.4) 2 (3.6)
Grade 2 (N, %) 58 (10.6) 15 (18.1) 21 (13.3) 16 (6.4) 6 (10.9)
Grade 3 (N, %) 79 (14.5) 22 (26.5) 21 (13.3) 32 (12.9) 4 (7.3)
Grade 4 (N, %) 345 (63.3) 27 (32.5) 100 (63.3) 175 (70.3) 43 (78.2)
CPGQ (von Korff)
Grade 1 (N, %) 138 (25.3) 39 (47.0) 43 (27.2) 50 (20.1) 6 (10.9)
Grade 2 (N, %) 122 (22.4) 21 (25.3) 36 (22.8) 56 (22.5) 9 (16.4)
Grade 3 (N, %) 212 (38.9) 22 (26.5) 63 (39.9) 97 (39.0) 30 (54.5)
Grade 4 (N, %) 73 (13.4) 1 (1.2) 16 (10.1) 46 (18.5) 10 (18.2)
Differences between modules were computed either with one-way analysis of variances (ANOVA [49]) or v2 tests, depending on the type of
variable. Means with different superscripts differ significantly (Tukey’s HSD)
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significantly less anxiety and depressive symptoms than
patients in modules 2 and 3, with the latter not differing
significantly. Correspondingly, the percentage of patients
with a HADS anxiety (v2(3) = 40.06, p \ 0.001) or
depression score (v2(3) = 23.34, p \ 0.001) above the
cutoff of 11 differed significantly between modules, with
the patients in modules 2 and 3 being most likely to have
an anxiety or mood disorder (see Table 3).
Health-related quality of life
With regard to physical HQoL, patients in module 0
reported a significantly higher level compared to the
patients in all other modules, with no significant difference
between modules 1, 2 and 3 (F(3,541) = 8.45, p \ 0.001;
see Table 3). With regard to psychological HQoL, the one-
way ANOVA also revealed a significant group main effect
(F(3,541) = 20.18, p \ 0.001). Similar to the findings
obtained for the HADS, the post hoc Tukey HSD contrasts
showed that patients in modules 0 and 1 reported a similar
level of psychological HQoL which was significantly lower
than in modules 2 and 3 patients which, in turn, were not
significantly different.
One-year follow-up
Mean reduction in HA frequency was 6.8 days/month.
Headache frequency decreased from 15.00 ± 8.19 to
8.22 ± 8.63 (-45.3 %) days/month (t = 5.056, df = 157,
p \ 0.001). 61.1 % of the patients (96/157) experienced a
reduction of HA frequency (N HA days per month) of
greater than 50 %. Headache-related disability (MIDAS)
decreased significantly from 55.96 ± 61.28 to 35.87 ± 55.09
(t = 4.924, df = 129, p \ 0.001). HADS anxiety was also
significantly lower at the 1-year follow-up (pre: M =
7.60 ± 4.24; follow-up: M = 6.66 ± 4.24; t = 2.567,
df = 91, p = 0.012). The level of depressive symptoms
(HADS) did not change significantly (pre: M = 5.70 ±
3.77; follow-up: M = 5.10 ± 4.54). Medication (analge-
sics, triptans, ergotamine) was used by 98.7 % of the
patients at baseline and by 89.9 % of patients at the 1-year
follow-up with a highly significant reduction in the number
of days with medication use per month (pre: M =
10.92 ± 7.31; follow-up: 3.99 ± 3.62; (t = 9.686, df = 157,
p \ 0.000). At baseline, 24 % of the patients reported an
intake frequency of C15 days/month. 57 % of patients
used acute medication on 6–14 days/month and 17.7 % on
1–5 days/month. At the end of treatment, only 1.3 % of the
patients consumed acute medication on C15 days/month,
23.4 % relied on acute medication on 6–14 days/month.
About two-thirds of the patients (65.2 %) used acute
medication on 1 up to 5 days/month. The number of
patients who abstained from acute medication increased
from 1.3 to 10.1 %. The number of patients who abstained
from acute medication increased significantly from 1.3 %
at baseline to 10.1 % at the end of treatment [v2
(61.348) = 43.4; df = 9; p \ 0.001].
Discussion
Providing efficient multidisciplinary treatment for difficult to
treat patients is a challenge. Few data exist on how to assign
patients to treatment and on effectiveness of such a multidis-
ciplinary integrated headache care program for patients with
frequent HAs, including MOH. A modularized program was
Table 3 Anxiety, depression and health-related quality of life (SF12) (M; SD) in the patients assigned to the four modules
Total Module 0 Module 1 Module 2 Module 3
HADS—Anxiety
Total score (M, SD) 7.13 (3.95) 5.23a (2.9) 5.85a (3.35) 8.35b (3.99) 8.18b (4.53)
T score (M, SD) 54.85 (11.4) 49.46 (9.68) 51.23 (10.58) 58.34 (10.94) 57.57 (12.00)
Above cutoff (N, %) 114 (20.9) 4a (4.8) 17b (10.8) 76c (30.5) 18d (32.7)
HADS—depression
Total score (M, SD) 5.57 (3.93) 3.7a (2.52) 4.31a (3.52) 6.69b (4.06) 6.91b (4.12)
T score (M, SD) 59.99 (11.48) 54.55 (8.89) 56.13 (11.2) 63.37 (10.99) 64.00 (11.46)
Above cutoff (N, %) 67 (12.3) 1a (1.2) 17b (10.8) 44c (17.7) 11d (20.0)
SF-12 (M, SD)
Physical 40.02 (8.00) 43.62a (6.50) 40.35b (7.62) 39.08b (8.24) 37.88b (8.47)
Psychological 45.08 (10.62) 50.13a (8.33) 40.08a (9.40) 42.07b (10.97) 42.47b (10.38)
Differences between modules were computed either with one-way analysis of variances (ANOVA [49]) or v2 tests, depending on the type of
variable. Means with different superscripts differ significantly (Tukey’s HSD)
HADS Hospital Anxiety and Depression Scale, SF-12 12 item version of the Short Form of Medical Outcomes Questionnaire
384 J Headache Pain (2012) 13:379–387
123
chosen, because this allows to tailor the treatment to an indi-
vidual’s needs, and because it is not the referring physician
who assigns the patient to specific interventions but treatment
assignment is based on a multidisciplinary assessment.
The primary goal of the present study was the validation
of a criterion-based patient assignment to the modules of
our integrated headache care program. Our results docu-
ment that the algorithm used to assign the patients to
treatment modules specifically designed to meet their need
works. A main aim was to offer managed health care for
out- and inpatients that is tailored individually using HA
frequency, analgesic consumption, and psychiatric comor-
bidity as criteria for treatment indication. Most of the
available interdisciplinary headache concepts only offer a
standardized program which does not allow an individual
adjustment based on patients’ needs [36, 37]. We devel-
oped a modularized headache treatment program with the
aim of treating chronic headache suffers according their
burden of disease. Patients are assigned to treatment
modules based on headache frequency, medication overuse
and psychiatric comorbidity. Most crucially, it needs to be
shown that this algorithm allows a valid patient assignment
with regard to headache-related disability and quality of
life. As was to be expected when HA frequency is used as
assignment criterion, HA frequency rose significantly from
modules 0 to 3 with a significant increase between each
module. By contrast, HA intensity was comparable in all
patients. Similarly, analgesic consumption differed signif-
icantly in the four modules. Patients assigned to module 3
reported significantly more days of analgesic consumption
and medication doses per month than those in the other
modules. Patients in module 2 relied on medication on
significantly fewer days per month than those in module 3,
but on significantly more days than those in modules 0 and
1. The total number of medication doses per month did not
differ significantly between modules 0, 1 and 2. These
results show that the patients’ assignment based on HA
frequency and medication use was well efficient.
Importantly, we aimed at validating patients’ assign-
ment to the different treatment modules with regard to
external criteria, such as headache-related disability and
health-related quality of life. The average MIDAS total
score was 43.3, ranging from 18.5 in module 0 to 61.4 in
module 3. Overall, these MIDAS scores well match those
previously reported for chronic headache sufferers [38, 39].
Disability in patients assigned to module 2 or 3 was
comparable. However, these patients were significantly
more disabled than patients in modules 0 and 1, with
patients in module 0 being also significantly less disabled
than patients in module 1. Correspondingly, the percentage
of patients having a MIDAS grade III or IV increased
significantly from module 0 to module 3. A rather similar
pattern was observed with regard to the von Korff chronic
pain grade questionnaire. Hence, both MIDAS and CPGQ
scores were highest in patients assigned to module 3 and
lowest in patients assigned to module 0. Module 2 patients’
disability was comparable to module 3 patients’ if the
MIDAS score was considered and comparable to module 1
patients’ if the CPGQ score was used. This difference is
most likely accounted for by the fact that MIDAS measures
disability primarily based on the number of days of lost
productivity (e.g., work), whereas the CPGQ relies on the
perceived degree of disability. Given that patients are
assigned to module 3 rather than 2 if there is psychiatric
comorbidity and not due to differences in HA activity and
use of medication, it is rather plausible that disability
determined based on the number of lost days due to HA
does not significantly differ between modules 2 and 3.
Consistent with the findings for HA disability, health-
related quality of life also varied between modules. With
regard to the SF12 physical scale, patients with no or little
chronicity (module 0) reported a significantly higher level
of health-related quality of life compared to the patients in
all other modules. By contrast, psychological functioning
(SF12 mental health scale) was highest in patients assigned
to modules 0 (no or less chronicity) and 1 (moderate
chronicity) and lowest in patients in modules 2 (severe
chronicity) and 3 (severe chronicity with additional prob-
lems). This pattern suggests that a HA frequency of more
than 5 days/month is associated with a distinct reduction in
physical functioning, whereas psychological quality of life
is strongly affected when HA frequency exceeds 10 days
per month. However, there is increasing awareness that
mood and anxiety disorders are positively correlated with
chronification of headache [40–42]. The observed decrease
in psychological functioning is most likely accounted for
by elevated anxiety and depression levels. Such an inter-
pretation is supported by the observed pattern of the anx-
iety and depression HADS scores. Patients in modules 0
and 1 had similar anxiety and depression levels and a
similar number of patients had HADS scores above the
cutoff. These patients were significantly less anxious and
depressed than the patients in modules 2 and 3, with no
significant difference between them. Clearly, we had
expected that patients assigned to module 3 would be
significantly more anxious and depressed than all other
patients, given that psychiatric comorbidity as assessed by
a clinical psychologist is a primary criterion for a patient’s
assignment to module 3. Our findings suggest that the
HADS was suitable for detecting patients with clinically
elevated levels of anxiety and depression. This has
important clinical implications as it suggest that patients
with frequent HAs should be routinely screened using the
HADS. The observed relationship between high HA fre-
quency, high use of analgesics, high pain-related disability
and high emotional distress is consistent with previous
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observations that psychiatric comorbidity contributes to the
chronicity and intractability of headache [41, 43].
A second aim of the present study was to provide pre-
liminary data on the effectiveness of this modularized HA
treatment program. In a subset of patients, the primary and
secondary outcome variables improved significantly. Specif-
ically, mean HA frequency decreased by about 6.8 days/
month. On average, HA frequency was reduced by 45.3 %.
This success rate is similar to previous studies which reported
improvements of about 35 % (e.g. Lemstra et al. [44]: 33.6 %
at 3-month follow-up; Gaul et al. [21]: 34.3 % at a follow-up
time between 12 and 18 months after the end of treatment).
The number of days with acute medication intake, known as
predictor of MOH [45], was also significantly reduced. The
percentage of patients who relied on non-pharmacological
self-management strategies increased from about 1.3 % at
baseline to 10.1 % after 1 year. At follow-up, only 1.3 % of
the patient used medication on more than 15 days per month,
at baseline 24 % of the patients showed this pattern of medi-
cation use. This reduction is impressive, because previous
studies have reported relapse rates of drug withdrawal of up to
40 % within 1 year [46–48].
Taken together, our study shows that using a simple
algorithm, it is feasible to assign HA patients to treatment
modules tailored to patients’ needs. Such a treatment
assignment to a modularized treatment program seems
promising for an effective and cost-efficient treatment of
chronic HA patients.
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